Micreos offers bacteriophage-based alternative to traditional antibiotics

Dutch biotech company Micreos' endolysin-based product Staphefeckt has shown promise in early case studies as a treatment for skin infections, exciting hopes of a new avenue of treatment in the battle against multi-drug antibiotic resistance.

Presenting the case studies at the EuroSciCon meeting in London, the company said its product Endolysin Staphefekt was able to kill Staphylococcus aureus, including methicillin-resistant S aureus (MRSA), leaving